492results about "Polypeptide with affinity tag" patented technology

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the invention, or nucleic acid molecules encoding them. The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention.

The invention belongs to the field of synthetic biology, and particularly relates to collagen fusion polypeptide as well as application and a preparation method thereof. The collagen fusion polypeptide provided by the invention comprises: (a) a first polypeptide of recombinant III-type collagen; and (b) a second polypeptide comprising a trimerized folding domain. The collagen fusion polypeptide provided by the invention has the advantages of low immunogenicity, good biocompatibility, high biological activity and the like, can significantly promote proliferation and migration of human skin fibroblasts, and has stronger ability of promoting regeneration of endogenous collagen. The collagen fusion polypeptide has a triple helix structure similar to natural collagen, and can be self-assembled to form collagenous fibers which are good in morphology and similar to natural collagen. The method can be widely applied to the fields of skin repair dressings, biological materials, artificial implants, medical instruments, cosmetics, health care products, food and the like.

Provided herein are fusion polypeptides comprising an amino acid sequence of a bacteriocin, the amino acid sequence of the bacteriocin being a cleavage intein both on both the N-terminus and on both the C-terminus that cyclizes the bacteriocin. Also provided are nucleic acids and genetic vectors encoding the fusion polypeptides, as well as microbial cells genetically engineered with the nucleic acids or genetic vectors. Also provided are methods of making the cyclic bacteriocin, methods of screening using a library of nucleic acids or genetic vectors encoding the fusion polypeptides, and methods of controlling growth of organisms using the cyclic bacteriocin made by the methods provided herein.

The present disclosure is generally related to methods and compositions for producing heterologous lectin proteins of interest in recombinant filamentous fungal cells. Certain embodiments are therefore, directed to compositions and methods for the production of lectin proteins, recombinant filamentous fungal strains comprising enhanced lectin protein productivity phenotypes, polynucleotides (e.g., expression constructs) encoding one or more lectin proteins, industrial scale fermentation, lectin protein recovery processes and the like.

The invention provides a plug-and-play Mi3 protein nanocage fusion protein with a VNP6 tag and a preparation method and application of the plug-and-play Mi3 protein nanocage fusion protein, the fusion protein comprises the VNP6 tag, a SpyCatch003 component, a Mi3 protein nanocage and a functional protein sequence, and the VNP6 tag is located at the N end of the fusion protein. The VNP6 peptide sequence or the variant thereof is utilized to induce a vesicle or vesicle-like structure beneficial to protein folding and stabilization in escherichia coli, so that the correct folding rate and activity of recombinant protein are improved while the overall intracellular molecular crowding effect is relieved. The core idea of the invention lies in that the internal structure of cells is regulated at low temperature, and the internal microenvironment of an escherichia coli expression system is optimized, so that protein molecules under high expression load can obtain more reasonable spatial distribution, and the problems of misfolding and aggregation caused by molecular crowding are reduced.

The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

The present disclosure relates generally to nucleic acid constructs comprising a nucleotide sequence comprising one or more pigment producing genes, wherein expression of the nucleotide sequence is under the control of a cotton fibre-specific promoter, and wherein the cotton fibre-specific promoter is capable of driving expression of the nucleotide sequence during two or more fibre development stages, and their use in the production of colour cotton fibre, or for the introduction of one or more pigment producing genes into a cotton plant. The present disclosure further contemplates cotton plants modified to produce cotton fibre, cotton seed, cotton lit, yarn, textiles and associated methods.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present invention relates to modified apolipoproteins with a targeting body. The targeting body may be, for example, an antibody or antigen-binding fragment that allows for targeting, for example, a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload in place of itself or when incorporated into lipid nanoparticles. The modified apolipoproteins may be used to treat or prevent a disease, or target a payload to a specific target site.

This invention provides vectors (e.g., lentiviral vectors) and expression cassettes for incorporation into vectors for expressing an alpha-globin (α-globin) gene. In certain embodiments method of treatment using such vectors are provided.

The invention discloses a virus-like structure nano adapter and application thereof, on the basis of hepatitis B virus core protein Uniprot P03146 of which nucleic acid binding domains at 145-183 sites of a C tail end are removed, CBP as shown in SEQ ID NO.01 is respectively inserted into a spike part and an N tail end of the hepatitis B virus core protein Uniprot P03146. The invention is constructed based on collagen combined polypeptide CBP designed by bionic decorrin, aims to imitate the interaction between natural decorrin and collagenous fiber, can efficiently cross over corneal epithelium barrier and repair corneal stroma in a non-photo-crosslinking manner, and solves the limitation of existing clinical treatment.

Disclosed herein, in some aspects, are compositions of lipid delivery particles used to deliver a payload to a target cell and methods of producing the like. Lipid delivery particles can comprise ectosomes, exosomes, nanoparticles, or other classes of extracellular vesicles suitable for transporting a payload. Lipid delivery particles can further comprise a chimeric protein comprising a plasma recruitment element and one, two, or all of: (i) a particle budding motif; (ii) a membrane penetrating peptide; (iii) a post-translational modification motif; and / or (iv) a multimerization motif. Additionally, disclosed herein, in some aspects, are nucleic acid molecules encoding the same.

Disclosed are endoglucanases having improved stability, e.g., in the presence of a prote-ase, and the use of such endoglucanases in detergent applications, such as laundry or dish wash.

The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Disclosed herein are immune cells expressing engineered cytokine receptor switches which, upon activation, can direct differentiation of the immune cells. The present disclosure further provides compositions and methods for transfecting, expanding, and activating these immune cells, including substrates which activate the engineered cytokine receptor switches disclosed herein.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. A preferred peptide includes the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. The peptides include the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

The invention discloses a gene for improving genetic transformation efficiency of wheat and application of the gene, and belongs to the technical field of plant genetic engineering. By utilizing the TaHRF1 gene and the encoded protein thereof, exogenous nucleic acid molecules can be promoted to be integrated into a target plant genome, the integration efficiency of the nucleic acid molecules is improved, the growth and development of transformed plants are normal, and the target plants comprise but are not limited to monocotyledonous plants such as wheat. An overexpression vector of the wheat TaHRF1 gene is constructed to infect explants of wheat with different genotypes. Statistical data shows that compared with a control vector, the overexpression vector of the TaHRF1 gene can promote nucleic acid molecules to be integrated into a genome of a target plant. By utilizing the TaHRF1 gene, the genetic transformation efficiency of a target gene introduced into a plant can be improved, the regeneration capacity and transformation efficiency of monocotyledonous plants, especially wheat, are improved, and the plant subjected to genetic transformation grows and develops normally. The invention provides a new important gene resource for overcoming genotype dependence of wheat genetic transformation.

Described herein are fusion proteins comprising an extracellular domain of an immune checkpoint receptor and a cytoplasmic domain of an activating receptor. Also described herein are fusion proteins comprising a cytoplasmic domain of an immune checkpoint receptor and an extracellular domain of an activating receptor. The present disclosure further provides methods of use of such fusion proteins.

The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples. The present disclosure provides methods for preparing cDNA and / or DNA molecules and cDNA and / or DNA libraries using modified reverse transcriptases.

The present invention relates to a fusion protein comprising a main protein and one or more extension peptides, wherein the amino acid sequence of the main protein is identical or similar to the amino acid sequence of a mammalian protein or a fragment thereof, and the extension peptides comprise a cluster of O-glycosylated amino acids. The extension peptide is identical to a non-repeated sequence of a mammalian protein and / or is identical or similar to SEQ ID NO:1. The main protein is preferably VWF. The fusion protein has an increased half-life compared to the main protein and can be used to increase the half-life of a binding partner, such as FVIII. The invention further relates to complexes formed by the fusion proteins, polynucleotides encoding the fusion proteins, and vectors and host cells containing the polynucleotides. [Selected Figure] Figure 1

A material with a scaffold comprising a series of at least partially spaced fibers and gas vesicles locates between fibers. The gas vesicles comprise external anchoring modules that are effective to anchor the gas vesicles to the fibers.

The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples. The present disclosure provides methods for preparing cDNA and / or DNA molecules and cDNA and / or DNA libraries using modified reverse transcriptases.

This application provides improved methods of genome editing. Cas9 molecules can be used to create a break in a genomic region of interest. To increase the likelihood that the break is repaired by HDR (homology-directed repair), the cell can be contacted with molecules that bring a template nucleic acid in close proximity to the break, under conditions that allow the cell to repair the break using the template nucleic acid.

The present invention relates to an artificially engineered CRISPR / Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR / Cas9 system including the same enzyme in genome and / or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

The present invention relates to the field of nucleic acid editing, and in particular to the technical field of clustered regularly interspaced short palindromic repeats (CRISPR). Specifically, provided are Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding same. Also provided are a complex and a composition for nucleic acid editing (e.g., gene or genome editing), comprising a Cas effector protein or a fusion protein, or a nucleic acid molecule encoding same. Also provided is a method for nucleic acid editing (e.g., gene or genome editing), which method uses a material comprising the Cas effector protein or the fusion protein.

Provided are compositions and methods for a cell population comprising engineered cytotoxic innate lymphoid cells engineered for controlled expansion and / or activity, the engineered cytotoxic innate lymphoid cells comprising a synthetic cytokine receptor for a non-physiological ligand. The cytokine receptor may comprise a synthetic gamma chain polypeptide as a first dimerization domain, a first transmembrane domain, and an interleukin-2 receptor subunit gamma (IL-2RG) intracellular domain and a synthetic beta chain polypeptide as a second dimerization domain, a second transmembrane domain, and an intracellular domain selected from an interleukin-2 receptor subunit beta (IL-2RB) intracellular domain, an interleukin-7 receptor subunit beta (IL-7RB) intracellular domain, and / or an interleukin-21 receptor subunit beta (IL-21RB) intracellular domain. The non-physiological ligand activates the synthetic cytokine receptor in the cytotoxic innate lymphoid cells to induce expansion and / or activation of the engineered cytotoxic innate lymphoid cells.

The present disclosure relates to novel cell wall binding domains, enzymatically active domains, and chimeric cell wall hydrolases with anti-Cutibacterium acnes activity. The disclosure also relates to compositions comprising these, and uses thereof in the treatment of conditions associated with Cutibacterium acnes.

Described herein are engineered proteins along with compositions and systems comprising an engineered protein. Also described herein are methods of using and / or producing an engineered protein such as methods of using an engineered protein for modifying or editing a target nucleic acid.